Dyne Therapeutics (DYN) Non-Current Debt (2020 - 2026)
Dyne Therapeutics' (DYN) quarterly Non-Current Debt came in at $149.4 million in Q1 2026, little changed on a QoQ basis from $148.9 million in Q4 2025.
Dyne Therapeutics (DYN) Non-Current Debt (2020 - 2026) Analysis & Trends
Dyne Therapeutics (DYN) has 3 years of Non-Current Debt data on file, last reported at $149.4 million in Q1 2026.
- On a quarterly basis, Non-Current Debt changed N/A year-over-year to $149.4 million in Q1 2026; TTM through Mar 2026 was $149.4 million, a N/A change from a year earlier, with the FY2025 full-year figure at $148.9 million, changed N/A from the prior year.
- Non-Current Debt for Q1 2026 stood at $149.4 million, roughly flat from $148.9 million in the prior quarter.
- Over the last five years, Non-Current Debt for DYN reached as high as $149.4 million in Q1 2026 and fell as low as $98.8 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 105.94 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 842.92 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.99 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Dyne Therapeutics | 3.94 Bn | 3.94 Bn | - | 149.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 149.38 Mn |
| Dec 31, 2025 | 148.92 Mn |
| Sep 30, 2025 | 99.15 Mn |
| Jun 30, 2025 | 98.81 Mn |
| Sep 30, 2020 | 9.94 Mn |